任小双，陈亚伟，吴玲玉，吕润玲，孟凡姗，都潇，张恒辉*
（臻和（北京）科技有限公司北京，100191）
图1 获批免疫治疗药物及适应证
表1免疫治疗生物标志物汇总
图2 液体活检临床应用价值
参考文献
1.Wen S,Dai L,Wang L，et al.Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in ChineseNon-Small CellLungCancer.Oncologist. Nov;24(11):e1070-e1081.
2.Wu YL,Saijo N,Thongprasert S，et al.Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter,IPASSstudy of first-line gefitinib versus carboplatin/paclitaxel in Asian patients withEGFRmutation-positive advanced NSCLC.Lung Cancer. Feb;104:119-125.
3.Abstract LBA2_PR‘Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA will be presented by Dr Suresh Ramalingam during Presidential Symposium I on Saturday 9 September , 16:30 to 18:00 (CEST) in the Madrid Auditorium.
4.Mehlman C,Cadranel J,et al.Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study.Send to
Lung Cancer. Nov;137:149-156.
5.Liu P, Wang Y, Li X. Targeting the untargetable KRAS in cancer therapy. Acta Pharmaceutica Sinica B. ;9(5):871-879. doi: 10.1016/j.apsb..03.002.
6.Gatalica Z,Xiu J,Swensen J,Vranic S.Molecularcharacterization of cancers withNTRKgene fusions.Mod Pathol. Jan;32(1):147-153.
7.Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion–positive cancers in adults and children. New England Journal of Medicine. Feb 22;378(8):731-9.
8.L. Paz-Ares, et al. Entrectinib in NTRK Fusion-Positive Non-Small Cell Lung Cancer (NSCLC): Integrated Analysis of Patients (pts) Enrolled in STARTRK-2,STARTRK-1 and ALKA-372-001. Abstract 113O, Presented at ELCC Annual Meeting; April 10-13, ; Geneva.
9.Hyman D, Kummar S, Farago A, et al. Phase I and expanded access experience of LOXO-195 (BAY 2731954), a selective next-generation TRK inhibitor (TRKi). Presented at: AACR Annual Meeting; March 29 to April 3, ; Atlanta, GA. Abstract CT127.
10.Helsten T,Elkin S,Arthur E,Tomson BN,Carter J,Kurzrock R.The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing.Clin Cancer Res. Jan 1;22(1):259-67.
11.Loriot Yohann,Necchi Andrea,Park Se Hoon et al. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.[J] .N. Engl. J. Med., , 381: 338-348.
12.Ledermann JA,Drew Y,Kristeleit RS。Homologous recombination deficiency and ovarian cancer.Eur J Cancer. Jun;60:49-58.
13.Nientiedt C,Tolstov Y,Volckmar AL,et al.PARPinhibition in BRCA2-mutated prostate cancer.Ann Oncol. Jan 1;28(1):189-191.
14.Golan T,Hammel P,Reni M,et al.Maintenance Olaparib for GermlineBRCA-Mutated Metastatic Pancreatic Cancer.N Engl J Med. Jul 25;381(4):317-327.
15.Yi T,Feng Y,Sundaram R,et al.Antitumor efficacy of PARP inhibitors in homologous recombination deficient carcinomas.Int J Cancer. Sep 1;145(5):1209-1220.
16.Helsten T,Elkin S,Arthur E,Tomson BN,Carter J,Kurzrock R.The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing.Clin Cancer Res. Jan 1;22(1):259-67.
17.Audeh W,Blumencranz L,Kling H,et al.Prospective Validation of a Genomic Assay in Breast Cancer: The 70-geneMammaPrintAssay and the MINDACT Trial.Acta Med Acad. Apr;48(1):18-34.
18.Jia Xin Yu,Jeffrey P. Hodge,Cristina Oliva,et al.Trends in clinical development for PD-1/PD-L1 inhibitors, retrieved /11/4.
19.Havel JJ,Chowell D,Chan TA.The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy.Nat Rev Cancer. Mar;19(3):133-150.
20.IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC).J Clin Oncol 37, (suppl; abstr 1003).
21.Spigel D, de Marinis F, Giaccone G, et al. IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC. Program and abstracts of the European Society for Medical Oncology Congress; September 27-October 1, ; Barcelona, Spain. Abstract LBA78.
22.Reck M,Rodríguez-Abreu D,Robinson AG,et al.KEYNOTE-024 3-Year Survival Update:Pembrolizumab vs Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer[EB/OL].WCLC ,abstract OA14.01;
23.Mok TSK,Wu YL,Kudaba I,et al.Pembrolizumab versus chemotherapy for previously untreated,PD-L1-expressing,locally advanced or metastatic non-small-cell lung cancer(KEYNOTE-042):a randomised,open-label,controlled,phase 3 trial[J].Lancet,,393(10183):1819-1830.
24.Hellmann MD,Paz-Ares L,Bernabe Caro R,et al.Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.N Engl J Med. Nov 21;381(21):-2031.
25.ASCO annual meeting. Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: phase 3 KEYNOTE-181 study.Shah MA,Kojima T,Hochhauser D,et al.Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2KEYNOTE-180Study.JAMA Oncol. Apr 1;5(4):546-550.
26.Matulonis U A, Frommer R S, Santin A D, et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study[J]. Ann Oncol, , 30:1080-1087.
27.Cao D,Xu H,Xu X,Guo T,Ge W.High tumor mutation burden predicts better efficacy of immunotherapy: a pooled analysis of 103078 cancer patients.Oncoimmunology. Jun 16;8(9):e1629258.
28.Paz-Ares L,Langer CJ,Novello S,et al.Pembrolizumab(pembro) plus platinum-based chemotherapy(chemo) for metastatic NSCLC:Tissue TMB(tTMB) and outcomes in KEYNOTE-021,189,and 407[EB/OL].ESMO ,abstract.
29.Herbst RS,Lopes G,Kowalski DM,et al.Association between tissue TMB(tTMB) and clinical outcomes with pembrolizumab monotherapy(pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and -042 trials[EB/OL].ESMO ,abstractLBA79.
30.Prospective clinical evaluation of blood-based tumor mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC): Interim B-F1RST results. ASCO, Abs 12001.
31.Wang Z, Duan J, Cai S, et al. Assessment of blood tumor mutational burden as a potential biomarker for immunotherapy in patients with non-small cell lung cancer with use of a next-generation sequencing cancer gene panel. JAMA oncology, .
32.Samstein Robert M,Lee Chung-Han,Shoushtari Alexander N et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types.[J] .Nat. Genet., , 51: 202-206.
33.Chalmers ZR,Connelly CF,Fabrizio D,Gay L, et al.Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.Genome Med. Apr 19;9(1):34.
34.Hause R J, Pritchard C C, Shendure J, et al. Classification and characterization of microsatellite instability across 18 cancer types[J]. Nature medicine, , 22(11): 1342.
35.Willis J, Lefterova MI, Artyomenko A, et al. Validation of microsatellite instability detection using a comprehensive plasma-based genotyping panel [published online ahead of print August 4, ].Clin Can Res.
36.Lu S,Stein JE,Rimm DL,Wang DW,et parison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis.JAMA Oncol. Jul 18.
Jun Wang, Jingwei Sun, Linda N. Liu, et al. Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy. Nature Medicine, .
Chin RI,Chen K,Usmani A,et al.Detection of SolidTumorMolecular Residual Disease(MRD) UsingCirculating Tumor DNA(ctDNA).Mol Diagn Ther. Jun;23(3):311-331.
Wang J,Chang S,Li G,Sun Y.Application of liquid biopsy in precision medicine: opportunities and challenges.Front Med. Dec;11(4):522-527.
40.Parikh AR,Leshchiner I,Elagina L,et al.Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers.Nat Med. Sep;25(9):1415-1421.
41.GRAIL to Present New Data in Late-Breaking Oral Presentation at the European Society for Medical Oncology (ESMO) Congress.
42.Head-to-Head Comparison to be Presented at AACR Supports Use of “Blood First” For First-Line Advanced NSCLC Patients. Retrieved February 28, .
43.Schochter F,Friedl TWP,deGregorio A，et al.Are Circulating Tumor Cells (CTCs) Ready for Clinical Use inBreast Cancer? An Overview of Completed and Ongoing Trials Using CTCs for Clinical Treatment Decisions.Cells. Nov 8;8(11).
44.Su Z,Wang Z,Ni X，et al.InferringtheEvolutionand Progression of Small-Cell LungCancerby Single-Cell Sequencing of Circulating Tumor Cells.Clin Cancer Res. Aug 15;25(16):5049-5060.
45.Pentsova EI,Shah RH,Tang J,et al.Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal Fluid.J Clin Oncol. Jul 10;34(20):2404-15.
Miller AM,Shah RH,Pentsova EI,et al.Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid.Nature. Jan;565(7741):654-658.
点击加入基因俱乐部 成就行业精英
目前已有500+行业精英加入基因俱乐部
如果觉得《肿瘤基因检测进展盘点》对你有帮助，请点赞、收藏，并留下你的观点哦！
